|
Khoom npe |
Teneligliptin hydrobromide hydrate |
|
CAS Nr |
1572583-29-9 |
|
Molecular Formula |
C22H33BrN6O2S |
|
Molecular Luj |
525.51 |
|
SMILES Code |
O=C([C@H]1NC[C@@H](N2CCN(C3=CC(C)=NN3C4=CC=CC=C4)CC2)C1)N5CSCC5.[H]Br.[H]O[H] |
Chemical Properties
Qhov kev sib xyaw no feem ntau tau txais los ua cov dawb rau tawm - cov hmoov dawb. Nws cov mis molecular yog sawv cev raws li C22H30N6OS · 5/2HBr · xH2O los yog raws li daim ntawv dimeric C44H67Br5N12O3S2, nrog ib tug sib xws molecular hnyav ntawm kwv yees li 1275.7 rau tag nrho hydrated ntsev. Nws yog soluble hauv dej thiab DMSO, nrog kev tshaj tawm txog kev solubility txog li 80 mg / mL hauv dej thiab 30-100 mg / mL hauv DMSO. Lub molecule yog yam ntxwv los ntawm yim hydrogen daim ntawv cog lus pub dawb thiab kaum peb hydrogen daim ntawv cog lus lees txais, nrog plaub lub ntsiab lus stereocenters. Cov hmoov yog ruaj khov mus txog peb xyoos thaum khaws cia ntawm -20℃thiab rau ob xyoos ntawm 4 degree. Cov tshuaj yuav tsum tau siv nyob rau hauv ib lub hlis thaum khaws cia ntawm -20℃thiab tiv thaiv los ntawm rov qab khov-thaw mus. Nws yuav tsum tau khaws cia rau hauv lub thawv kaw kom deb ntawm lub teeb thiab noo noo.
Kev piav qhia
Teneligliptin hydrobromide hydrate yog hydrobromide ntsev thiab hydrated daim ntawv ntawm Teneligliptin, lub hwj chim, qhov ncauj bioavailable, thiab ntev -ntev inhibitor ntawm enzyme dipeptidyl peptidase-4. Tshuaj, nws yog ib tug prolylthiazolidine-raws li compound uas muaj ib tug complex qauv nrog ntau chiral chaw. Cov molecule suav nrog ib lub nplhaib pyrazole, ib lub nplhaib piperazine, thiab thiazolidine moiety, uas ua ke muab siab affinity thiab selectivity rau DPP-4 active site. Raws li kev sib tw inhibitor, nws khi rau thiab thaiv qhov kev txiav txim ntawm DPP-4, ib qho enzyme lub luag haujlwm rau kev degradation sai ntawm cov tshuaj hormones incretin xws li GLP-1. Los ntawm inhibiting cov enzyme no, nws prolongs ib nrab-lub neej thiab txhim khu kev ua haujlwm ntawm cov tshuaj hormones, ua rau kev txhim kho cov ntshav qabzib.
Siv
Antidiabetic Agent
Teneligliptin hydrobromide hydrate yog cov khoom siv tshuaj nquag hauv cov tshuaj pom zoo rau kev kho mob ntawm hom 2 mob ntshav qab zib mellitus. Raws li DPP-4 inhibitor, nws yog siv los txhim kho glycemic tswj hauv cov neeg laus. Nws muaj kev sib tw inhibits tib neeg recombinant DPP-4 nrog lub zog siab, nthuav tawm IC50 tus nqi ntawm kwv yees li 0.889 nM, thiab qhia tau hais tias muaj txiaj ntsig zoo sib xws rau tib neeg thiab nas ntshav ntshav DPP-4.
Mechanism ntawm Action Research
Qhov kev sib xyaw no ua haujlwm tseem ceeb hauv kev tshawb fawb pharmacological los tshawb xyuas qhov system incretin thiab nws lub luag haujlwm hauv glucose homeostasis. Kev tshawb fawb tau pom tias nws inhibits cov qabzib siab -kev kho mitochondrial tsis ua haujlwm, qhia txog lub peev xwm tiv thaiv kev tiv thaiv tshaj nws cov thawj enzyme inhibition. Nws yog siv nyob rau hauv kev ntsuam xyuas ntawm tes los kawm txog nws cov teebmeem ntawm oxidative kev nyuaj siab cov cim thiab cov noob qhia hauv vascular endothelial hlwb.
Kev tshawb fawb txog kev kho mob
Nyob rau hauv ntev -cov kev tshawb fawb preclinical lub sij hawm, Teneligliptin hydrobromide hydrate yog siv los soj ntsuam cov txiaj ntsig ntawm DPP-4 inhibition. Kev kho mob ntev ntawm ntau qhov ntau tau pom tias txo qis hyperglycemia-vim cov cim kev ntxhov siab tsis cuam tshuam rau cell viability, ua rau nws muaj txiaj ntsig zoo rau kev nkag siab txog kev mob ntshav qab zib.
Analytical Reference Standard
Cov khoom siv dav siv los ua tus qauv siab -purity reference standard for analytical method development, quality control, and regulatory compliance in the pharmaceutical industry. Nws yog siv rau kev sim thaum lub sij hawm tsim cov txheej txheem ntawm Teneligliptin-raws li tshuaj, nrog rau txoj kev validation thiab raws li ib tug siv rau abbreviated daim ntawv thov tshuaj tshiab.
Cim npe nrov: Tuam Tshoj Teneligliptin Hydrobromide Hydrate Manufacturers thiab lwm tus neeg
